Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Premixed and Basal-Bolus Insulin Intensification in T2DM
NCT01175811Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2011
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of insulin lispro + insulin lispro protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in Haemoglobin A1c (HbA1c) From Baseline to 24 Week Endpoint. Started Feb 2011; status: completed.
02
Drugs
insulin lispro + insulin lispro protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01175811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175811.